XML 25 R11.htm IDEA: XBRL DOCUMENT v3.22.4
Financial Instruments
12 Months Ended
Dec. 31, 2022
Financial Instruments, Owned, at Fair Value, by Type, Alternative [Abstract]  
Financial Instruments

 

The following is a summary of available-for-sale marketable securities, as of December 31, 2022 and 2021, respectively (in thousands):

 

 

December 31, 2022

 

 

Amortized Cost

 

 

Unrealized Gain

 

 

Unrealized Losses

 

 

Fair Value

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

Corporate securities (1)

$

184,321

 

 

$

75

 

 

$

(2,344

)

 

$

182,052

 

U.S. treasury and agency securities

 

34,071

 

 

 

3

 

 

 

(200

)

 

 

33,874

 

Total marketable securities

$

218,392

 

 

$

78

 

 

$

(2,544

)

 

$

215,926

 

(1) Comprised primarily of corporate bonds and commercial paper

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

December 31, 2021

 

 

Amortized Cost

 

 

Unrealized Gain

 

 

Unrealized Losses

 

 

Fair Value

 

Marketable securities:

 

 

 

 

 

 

 

 

 

 

 

Corporate securities (1)

$

7,716

 

 

$

 

 

$

(1

)

 

$

7,715

 

U.S. treasury and agency securities

 

6,070

 

 

 

 

 

 

(3

)

 

 

6,067

 

Total marketable securities

$

13,786

 

 

$

 

 

$

(4

)

 

$

13,782

 

(1) Comprised primarily of corporate bonds and commercial paper

 

 

 

 

 

 

 

 

As of December 31, 2022, the fair values of available-for-sale marketable securities, by remaining contractual maturity, were as follows (in thousands):

 

Due within one year

 

 

 

 

 

 

$

111,566

 

Due in one to five years

 

 

 

 

 

 

 

104,360

 

Total

 

 

 

 

 

 

$

215,926

 

 

The Company typically invests in highly rated securities, with the primary objective of minimizing the potential risk of principal loss. The Company’s investment policy generally requires securities to be investment grade and limits the amount of credit exposure to any one issuer. Fair values were determined for each individual security in the investment portfolio.

 

The Company does not believe that any unrealized losses are attributable to credit-related factors based on its evaluation of available evidence. To determine whether a decline in value is related to credit loss, the Company evaluates, among other factors: the extent to which the fair value is less than the amortized cost basis, changes to the rating of the security by a rating agency and any adverse conditions specifically related to an issuer of a security or its industry. The Company does not intend to sell the instruments and it is not more likely than not that the Company will be required to sell the investments before recovery of their amortized cost bases, which may be maturity. Unrealized gain and losses on marketable securities are presented net of tax.